Scholarlink

Background <p>Colorectal cancer (CRC) is the third most diagnosed cancer worldwide. Despite treatment advances, CRC still requires novel strategies to overcome drug resistance and metastasis. Midline 1 Interacting Protein 1 (MID1IP1) is highly expressed in cancers and promotes tumor growth through c-Myc-mediated ribosomal protein regulation. We hypothesized that MID1IP1 contributes to CRC progression via c-Myc and ferroptosis.</p> Objective <p>To investigate how MID1IP1 affects metabolic reprogramming, ferroptosis, and migration in CRC.</p> Methods <p>MID1IP1 was silenced in HCT116 cells using siRNA. Colony formation assays evaluated growth. Western blotting assessed c-Myc, ferroptosis-related proteins, glycolytic enzymes, and EMT markers. Intracellular ROS was measured with a fluorescence probe, and a ferroptosis inhibitor confirmed ferroptotic cell death. Immunofluorescence detected c-Myc and PKM2, while wound healing assays evaluated migration.</p> Results <p>MID1IP1 knockdown reduced cell growth and c-Myc stability, lowering glycolysis-related protein expression. GPX4 and other ferroptosis-protective proteins decreased, resulting in ROS accumulation and ferroptosis. Migration was inhibited, with altered EMT marker expression.</p> Conclusion <p>MID1IP1 promotes CRC cell survival by stabilizing c-Myc and preventing ferroptosis, while also influencing migration. These findings suggest that MID1IP1 may serve as a novel biomarker and therapeutic target in CRC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inhibition of MID1IP1 induces ferroptosis and suppresses c-Myc expression in colorectal cancer cell

  • 期刊论文

  • 发表日期：

    2025年12月4日

查看全文
  • Je Joung Oh,
  • Yu Jin Lee,
  • Yeo Jeong Han,
  • Yui Sasaki,
  • Jinbong Park,
  • Woojin Kim,
  • Ji Hoon Jung

摘要

Background

Colorectal cancer (CRC) is the third most diagnosed cancer worldwide. Despite treatment advances, CRC still requires novel strategies to overcome drug resistance and metastasis. Midline 1 Interacting Protein 1 (MID1IP1) is highly expressed in cancers and promotes tumor growth through c-Myc-mediated ribosomal protein regulation. We hypothesized that MID1IP1 contributes to CRC progression via c-Myc and ferroptosis.

Objective

To investigate how MID1IP1 affects metabolic reprogramming, ferroptosis, and migration in CRC.

Methods

MID1IP1 was silenced in HCT116 cells using siRNA. Colony formation assays evaluated growth. Western blotting assessed c-Myc, ferroptosis-related proteins, glycolytic enzymes, and EMT markers. Intracellular ROS was measured with a fluorescence probe, and a ferroptosis inhibitor confirmed ferroptotic cell death. Immunofluorescence detected c-Myc and PKM2, while wound healing assays evaluated migration.

Results

MID1IP1 knockdown reduced cell growth and c-Myc stability, lowering glycolysis-related protein expression. GPX4 and other ferroptosis-protective proteins decreased, resulting in ROS accumulation and ferroptosis. Migration was inhibited, with altered EMT marker expression.

Conclusion

MID1IP1 promotes CRC cell survival by stabilizing c-Myc and preventing ferroptosis, while also influencing migration. These findings suggest that MID1IP1 may serve as a novel biomarker and therapeutic target in CRC.